Table 1.

Detailed clinical information and patient annotations on the 20 breast cancer patients included in the study.

Patient ID	Age	HER2	Estrogen receptor	Progesterone receptor	Neoadjuvant chemotherapy*
001GY	49	3+	positive	positive	EC –> DTP
002GY	41	negative	negative	negative	Dtx –> EC
003GY	43	negative	positive	positive	EC –> Dtx
005GY	52	negative	negative	negative	EC –> Dtx
007GY	65	3+	positive	positive	EC –> DTP
009GY	42	3+	positive	positive	EC –> DTP
010GY	36	negative	positive	negative	EC –> Dtx
011GY	60	3+	positive	negative	EC –> DTP
013GY	63	negative	positive	negative	EC –> Dtx
014GY	64	negative	positive	positive	EC –> Dtx
015GY	46	3+	negative	negative	DTP –> EC
016GY	64	negative	positive	positive	EC –> Dtx
017GY	58	negative	positive	negative	EC –> Dtx
018GY	33	negative	positive	positive	EC –> Dtx
019GY	62	negative	positive	positive	EC –> Dtx
022GY	44	3+	negative	negative	EC –> DTP
023GY	60	3+	positive	positive	EC –> DTP
025GY	31	negative	positive	positive	Dtx –> EC
026GY	52	negative	negative	negative	Dtx –> EC
027GY	65	3+	negative	negative	EC –> DTP

*EC, epirubicin + cyclophosphamide; DTP, docetaxel + trastuzumab + pertuzumab; Dtx, docetaxel.